Coeptis Therapeutics Holdings Inc. COEP 深 沪
等待开盘 02-04 09:30:00 美东时间
13.52
-0.625
-4.42%
华盛通- 最 高14.44
- 今 开14.24
- 成交量 5.04万股
- 最 低 13.22
- 昨 收 14.145
- 总市值 7219.82万
- 52周最高 21.41
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 6.26
- 委 比 92.52%
- 总股本 534.01万
- 历史最高 428.40
- 量 比 0.89
- 振 幅 8.62%
- 历史最低 2.622
- 每 手 1
- 风险率 2.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Coeptis Therapeutics Addresses Nasdaq Listing Compliance Deficiency
Coeptis Therapeutics Holdings ( ($COEP) ) just unveiled an update. On January 1...
01-17 06:03
Coeptis Therapeutics' SEC-Approved S-4 Clears Path For Z Squared Merger, Stockholder Vote Set For January 30
Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, , announced today that its registration statement on Form S-4 (File No. 333-288329)
01-06 21:23
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its registration statement on Form S-4, related to its merger with Z Squared Inc. (ZSQ), has been declared effective by the SEC. The company will hold its Annual/Special Meeting of Shareholders on January 30, 2026, and has begun mailing the definitive proxy statement/prospectus to its shareholders of record as of January 2, 2026. The combined company has applied to list its common ...
01-06 13:19
Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating
Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track model to sustain innovation while reducing reliance on dilutive funding. In Q2 2025, the company generated $200,681 in revenue while advancing its GEAR Cell Therapy Platform for cancer treatment. Its NexGenAI platform provides complementary revenue streams, allowing the company to maintain control over research and equity. The global cell therapy market's growth presents opportunities...
2025-09-23 12:00
Coeptis Therapeutics Q2 EPS $(1.17) Up From $(1.60) YoY, Sales $200.681K
Coeptis Therapeutics (NASDAQ:COEP) reported quarterly losses of $(1.17) per share. This is a 26.88 percent increase over losses of $(1.60) per share from the same period last year. The company reported $200.681 thousand
2025-08-15 05:48
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
Coeptis Therapeutics Holdings, Inc. announced the extinguishment of its convertible note with YA II PN, Ltd (Yorkville), eliminating its debt obligations to the company. CEO David Mehalick stated this strengthens the Company’s capital structure, aiding in strategic expansion into the cryptocurrency space. Coeptis focuses on developing innovative cell therapies, with assets including allogeneic cellular immunotherapy and unmodified natural killer ...
2025-07-22 12:36
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: COEP, RHE, PPBI, and PORT
NEW YORK, July 3, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...
2025-07-04 05:31
Coeptis Therapeutics Files Form S-4 With SEC For Proposed Merger With Z Squared
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the filing of a registration statement on Form S-4 with the
2025-06-26 20:37
Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared
Coeptis Therapeutics Holdings, Inc. announced the filing of a Form S-4 registration statement with the SEC regarding its proposed merger with Z Squared Inc. The transaction involves combining Coeptis, a biopharmaceutical and technology company focused on cell therapies, with Z Squared, a digital asset mining company. The Form S-4 includes a preliminary proxy statement/prospectus, which will be finalized once the registration statement is effectiv...
2025-06-26 12:34
SNAP Biosciences & Monarch Therapeutics Partner To Advance Snap-Car NK Cell Therapy
SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (NASDAQ:COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a
2025-05-28 20:29
